Karyopharm Therapeutics Inc. (KPTI) Form 8-K — Jul 17, 2026

$KPTIForm 8-KItems 5.02Filed Jul 17, 2026, 5:01 PM ET0001193125-26-307964Original filing

Karyopharm Therapeutics implemented a cash retention program for its named executive officers and the Chief Financial Officer to incentivize continued leadership during a period of anticipated meaningful business catalysts. The 2026 Leadership Cash Retention Program replaces previously guaranteed annual bonus amounts and provides lump sum awards totaling $3.7 million to key executives, including $1.7 million to CEO Richard Paulson.

Key figures

Retention Award Paulson: 1725000
Retention Award Poulton: 640000
Retention Award Macomber: 625000
Retention Award Rangwala: 725000

Price after filing

1 day: 0.0%7 days: -22.1%30 days: -78.8%

Close on the filing date to close N calendar days later (from $9.51). Historical, not a forecast.

AI analysis

Red flags2 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

Upgrade to Pro · $49/mo billed annually

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.